Trials involving genomic-driven treatment selection require the coordination of many teams interacting with a great variety of information. The need of better informatics support to manage this complex set of operations motivated the creation of OpenGeneMed. OpenGeneMed is a stand-alone and customizable version of GeneMed (Zhao et al. GeneMed: an informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials. Cancer Inform 2015;14(Suppl 2):45), a web-based interface developed for the National Cancer Institute Molecular Profiling-based Assignment of Cancer Therapy (NCI-MPACT) clinical trial coordinated by the NIH. OpenGeneMed streamlines clinical trial management and it can be used by clinicians, lab personnel, statisticians and researchers as a communication hub. It automates the annotation of genomic variants identified by sequencing tumor DNA, classifies the actionable mutations according to customizable rules and facilitates quality control in reviewing variants. The system generates summarized reports with detected genomic alterations that a treatment review team can use for treatment assignment. OpenGeneMed allows collaboration to happen seamlessly along the clinical pipeline; it helps reduce errors made transferring data between groups and facilitates clear documentation along the pipeline. OpenGeneMed is distributed as a stand-alone virtual machine, ready for deployment and use from a web browser; its code is customizable to address specific needs of different clinical trials and research teams. Examples on how to change the code are provided in the technical documentation distributed with the virtual machine. In summary, OpenGeneMed offers an initial set of features inspired by our experience with GeneMed, a system that has been proven to be efficient and successful for coordinating the application of next-generation sequencing in the NCI-MPACT trial.
Introduction
Over the past decade, next-generation sequencing (NGS) technologies have been shown to be powerful tools for the clinical diagnosis and treatment selection for patients with cancer and other diseases, owing to the increase of sequencing speed, reduction of cost and improvement in accuracy [1] . Precision medicine treatments for cancer are gaining momentum owing to the rising interest in approaches guided by NGS [2] [3] [4] [5] [6] [7] .
The National Cancer Institute (NCI) is now conducting a clinical trial (NCT01827384) titled Molecular Profiling-based Assignment of Cancer Therapy (MPACT) to treat late-stage cancer patients based on their gene mutation profile [8] . Patients with solid tumors who have exhausted standard treatments undergo biopsy and have their tumors characterized based on DNA sequencing of >380 unique actionable variants in 20 genes. In the NCI-MPACT trial, several treatment regimens are used and the sequencing assay is designed to identify mutations likely to de-regulate some specific pathways (for details about the trial we refer to [8] ). Mutations are called actionable if they fulfill protocol-specified rules. The rules for actionability were derived combining information from literature, evidence of functional effects for loss-of-function genes and entries in the Catalogue of Somatic Mutations in Cancer (COSMIC) database [9] . Patients whose tumors contain at least one actionable mutation are randomized to either the actionable study treatment prospectively identified to work on that mutation/pathway or a control arm consisting of one of the other treatments available on the study.
The informatics support needed to coordinate the complex set of rules and operations of this clinical trial motivated the creation of the informatics system called GeneMed [10] . Similar principles have been used to develop the open and customizable version presented in this article, called OpenGeneMed.
The two core concepts behind OpenGeneMed are as follows: (1) provide a platform for annotating NGS data and (2) serve as an everyday tool to coordinate the management of a clinical study. There are existing tools that tackle those problems separately but none of them combines these features in an opensource environment. In the "Related Work" section we list some of the related platforms and highlight how OpenGeneMed differs from them.
With respect to GeneMed, this is a new distributable version that allows for easy customization of study-related information. Users can define rules to call a genetic variant 'actionable', populate the list of the drugs used in the study together with the target gene/pathway and integrate the support for different Variant Calling Format (VCF, https://github.com/samtools/htsspecs).
A key feature of the system is to serve as a communication hub linking the different teams involved in daily management of a clinical trial (sequencing lab, treatment review team, clinic team, statisticians, researchers, etc.). The system must have the ability to quickly annotate the sequencing data and match the detected mutations to the pre-identified genomic variants [i.e. the aMOI (actionable mutations of interest)]. The informatics hub has the ability to translate and present the mutation findings from sequencing results into a concise and easy-to-read actionable report for the treatment review team in a timely manner. This information is used by the team to assign patients to different arms based on their detected mutations. Clinical trials follow a variety of strategies to assign patients to treatment arms, one of the most commonly used being randomization. While the GeneMed system includes the assignment of the patient to the proper treatment based on randomization tables, OpenGeneMed does not include a module to do this assignment automatically because we designed the system to be useful for all kind of trials, whether randomized or not. However, the architecture of the system allows for easy integration of additional modules: in this way the addition of an automated (or semi-automated) treatment assignment module should be an easy task for the IT group that manages OpenGeneMed for the research study.
OpenGeneMed contains a module to collect and store patient data, including data from prior therapies, as this is critical to evaluate treatment eligibility, assisting the treatment review team and the clinic team in the development of a treatment plan. The system is also equipped to make both sequencing data and clinical outcome data available to statisticians to evaluate whether there is any improvement in response rate or progression-free survival favoring assignment of therapy based on genetic sequencing and to determine which actionable mutation-treatment pairs lead to improved patient outcome.
OpenGeneMed contains an administrative module that allows system administrators to register users with different roles (e.g. Clinical Team, Lab Team, Treatment Review Team). Each group will be granted different permissions on data monitoring, uploads and changes. This module, as all others in OpenGeneMed, is customizable and extendable so that each clinical trial setup and workflow can be easily mapped into the system.
OpenGeneMed is distributed as a stand-alone virtual machine (VM), ready for deployment and use from a web browser. The initial machine is configured with actual storage 1.6 GB (virtual storage 8 GB) and 5 GB RAM, but the VM can be configured to work on different hardware, and options involving clusters or cloud storage can be included using standard Linux setups.
In conclusion, we have developed an informatics system (OpenGeneMed) that, inspired by the GeneMed system, fulfills the tasks required by a clinical trial for guiding treatment based on sequencing information from patient's tumors.
Related work
In this section, we list some of the existing platforms that implement features similar to OpenGeneMed, and we highlight how OpenGeneMed differs from them.
A wide collection of bioinformatics tools exist for NGS data analysis; however very often they focus on specific aspects of the analysis (e.g. alignment or variant calling) [11] . Graphic User Interfaces and Web Interfaces are available for some applications, but many existing solutions rely on command line interfaces to execute custom scripts. Generating and disseminating clinically meaningful and comprehensive reports of NGS data between the different teams in the everyday practice of a clinical trial has historically received little attention from vendors of NGS data analysis solutions.
Recently, however, there have been efforts to build NGS annotation and reporting systems for clinical applications. Notable examples include the Clinical Genomicist Workstation developed by Washington University Genomic and Pathology Services to support sequencing data tracking and reporting for pathologists [12] , SeqReporter developed by the University of Pittsburgh Medical Center to automate NGS results interpretation and workflow reporting in a clinical molecular lab [13] and the Knowledge and Data Integration system recently developed in support of the SHIVA clinical trial at Institut Curie [14] . These, as several other tools for NGS data processing described in a recent review [15] , offer interesting analytical and ready-to-use functionalities for data queries and user analysis. However, they are often designed to handle a specific data type, they do not manage the information generated by the different teams in real-time, they do not provide clinicians with clinically meaningful summaries of the analyses and they do not allow easy plug-in of new functionalities or changes of the existing approaches. Moreover, several existing platforms are not available for local deployment as they use a client/server architecture, for which the server is not controlled by the final user.
Other platforms that offer clinical data management and data capture include commercial products like Oracle Clinical (www.oracle.com/us/products/applications/health-sciences/eclinical/clinical/index.html), as well as open-source options like OpenClinica (www.openclinica.com) and openCDMS [16] . While they offer good level of support for typical studies, with core functionalities for monitoring and processing clinical trial data as electronic data capture, input validation, user access control and study metadata, they do not offer direct annotation capabilities for the new generation of trials involving NGS. In addition, investing in commercial products could cost hundreds or thousands of dollars, depending on the size of the trial and number of licenses needed. With OpenGeneMed's free 'out-of-the-box' setup, we want to enable a wide variety of studies to be managed in a centralized, but extendable, way.
Other resources partially related to OpenGeneMed are databases containing information used to assess the actionability of genetic mutations or drug-related information. These resources differ from the main goal of OpenGeneMed: they are knowledge resources for physicians, patients and researchers and they make information accessible, but they do not provide a communication hub for the day-to-day management of a clinical study. The information from literature search about the biology of the disease, pre-clinical studies and approved drug should be coupled with access to resources like DrugBanK [17] , DGIdb [18] and ClinicalTrials.gov as part of the study protocol, a step that precedes the use of OpenGeneMed.
The NCI developed an informatics solution, called GeneMed [10] , which integrates a 'Lab review' feature and can automatically perform patient randomization based on mutation information for targeted genes. In GeneMed, each task requires a short amount of time when the necessary documents and information are ready. Data upload and annotation usually take <2 min on average-size VCF files (produced by TorrentSuite version 4.0.2. The raw data are processed using a bioinformatics pipeline for sequence alignment and variant calling. The sequencing is based on amplicon sequencing of >380 unique actionable variants in 20 genes [19] .). The lab team requires about 5-10 min to review the variant report, while the clinic team takes about 10-15 min to enter the clinical information. After the treatment, review team reaches an agreement on candidate treatment agent(s) for target arm and control arm by reviewing the patient clinical information, prior treatments and actionable mutations in the uploaded biopsy sample (usually less than half a day), one of the members submits the mutation summary in GeneMed. The recommended treatment assignment is determined by the system after the mutation summary is submitted. GeneMed is a unique web-based informatics system that connects NGS technology to precision medicine applications in real time and addresses the complex requirements imposed by a sequencing-guided randomized clinical trial.
Motivated by the experience gained with the GeneMed system, and by the idea that clinical trials management involves steps and teams that are similar albeit different in each situation, we developed our open-source informatics solution, OpenGeneMed. The main difference between the two systems is that GeneMed's ideas have been implemented in a distributable platform that can be extended and adapted to different studies, while GeneMed only focus on the specific details of MPCAT and cannot be used outside that study. Table 1 lists in more details the key differences and contributions that OpenGeneMed offers compared with GeneMed.
System design and architecture
The main goal of our system is to build a reliable, effective and easy-to-use bioinformatics platform that provides a seamless bridge between the different teams involved in running a clinical study and a system that can be used for everyday communication in real time.
OpenGeneMed is designed to be customizable to address the needs of different studies. However, a setup inspired by our experience with the GeneMed system is available in the initial configuration of the system.
A distributable version of OpenGeneMed and its user manual can be downloaded from http://brb.nci.nih.gov/OpenGeneMed. In this section, we describe all the features available 'out the box', showing that the system provides valuable support for the management of a clinical study in its basic installation. In Section "Customizing study's specific information", we outline how to customize existing modules and how to integrate new ones to better match more specific needs.
Working groups for a basic study
There are six groups of people who are involved in the management of a basic precision medicine trial. The tasks of these groups are as follows:
1. Admin Group: have access to all the different parts of the system. They are responsible for registering new users, assigning them to different groups and updating their information as necessary; 2. Study Coordinator: responsible for editing the eligibility questions, the actionable mutation rules and the gene/drugs of interest for the study; 3. Lab Team: lab members who perform the NGS assays and sequence validation. They are responsible for uploading the variant files and for reviewing aMOI identified by the OpenGeneMed system. One or more members of this group should act as 'chief' with additional responsibilities, such as managing delinking of patient identification and coordinating with other groups if changes in the study protocol occur; 4. Clinic Team: treating physicians and nurses who recruit and register patients, gather personal clinical information, treat patients and delink them after the patient's disease has progressed or when the patient is taken off the study. One or more members of this group should act as 'chief' with additional responsibilities, such as coordinating with the lab team on delinking of patient identification; 5. Treatment Review Team: access the patient clinical information, variant calls and decide on which treatment each patient should receive. This group allows a clear separation (blinding/masking) between the people that have access to the genetic information of the patient and the ones that deliver the actual treatment; 6. Biostatistics Group: researchers who are involved in the design of the study, monitor accrual rates and analyze the data as required by the study protocol.
Each group can only access information related to the assigned tasks of the group. For example, staff in the lab group can access sequence data along with limited non-editable patient clinical information; members of the clinic group, instead, can access patient clinic information but not sequence data before the patient is off study. Figure 1 summarizes the main tasks of each team.
Communication and operation flow of different groups in a basic study
Managing a clinical study is a complex operation that requires accuracy and team work, and so it is necessary for the different groups to work collaboratively to accomplish the tasks required by the study. The basic work flow and communications among different user groups are shown in Figure 2 , where all major tasks for each working group are sequentially ordered from top to bottom.
Once the Admin Team sets up accounts for the different team members, each of them will be able to access the part of OpenGeneMed devoted to their specific task. When a new patient enters the study, a member of the clinic group logs into OpenGeneMed and registers the patient using a clinical trial assigned patient ID (protocol ID). Some basic demographic information for the patient can be entered into the system. OpenGeneMed performs some standard validation for the input information (e.g. check the uniqueness of the patient ID, make sure that dates are in reasonable format): more details on the specific validation can be found in the technical documentation of OpenGeneMed. Patient clinical information includes previous treatments, response data and eligibility questions. Customization of the latter can be done by the Study Coordinator directly from the web interface, while examples on how to customize other parts of the clinical interface are presented in the User Manual to illustrate the flexibility of OpenGeneMed architecture.
After the patient has been registered, the sample can be collected and delivered to the sequencing lab. The lab receives the sample and performs the sequencing assay. The raw data are then processed in the lab using a bioinformatics pipeline for sequence alignment and variant calling external to OpenGeneMed. A file containing the variants in VCF version 4.2 (https://github.com/samtools/hts-specs) is generated after sequence alignment and quality control. At this point, the lab member goes into the OpenGeneMed system and uploads the VCF file.
OpenGeneMed stores the VCF file, automatically performs annotation of each variant and produces a report of the variant calls, using the customized rules previously recorded in the system by the Study Coordinator. The basic configuration of the system uses snpEff variant annotation and effect prediction tool [20] . SnpEff annotates variants as either synonymous or non-synonymous and the predicted amino acid change. OpenGeneMed further enriches the annotation with information about homopolymer regions within the amplicons: if the reported position is within 1 bp of any homopolymer region, the annotation will indicate the length of the homopolymer region. The variants are finally compared with a table of aMOI derived from literature, evidence of functional effects for loss-offunction genes and entries in COSMIC database. In the demo of OpenGeneMed, we provide few examples of actionable mutations, and it is the Study Coordinator's responsibility to customize the list following the study protocol (more details on the process are presented in the "Customizing study's specific information" Section). These mutations, including single nucleotide variants (SNVs) and insertion/deletion variants (indels), are known to be somatically altered in solid tumors based on recent scientific and clinical literature. The observed variants are marked if they match a variant in the aMOI table with their COSMIC ID. A variant is considered actionable if the detected genomic alteration is in the pre-defined aMOI list or if the alteration meets one of the pre-defined actionability rules. Rules can be modified, added or deleted to meet the needs of each study, more on this in the "Customizing study's specific information" Section. Information about the VCF submission (date and submitter identity) is recorded and an email is sent to the sequencing lab indicating a new variant file has been processed and it is ready for review.
After receiving the email notification, the lab reviewer logs into OpenGeneMed and begins the manual reviewing process following standard operating procedures. The reviewer checks and assigns a review status of either approved or rejected to each variant identified as 'aMOI' by OpenGeneMed. Rules to review aMOIs are different in each study protocol: for example, part of the approval/rejection procedure in the NCI-MPACT study [8] is to reject aMOI calls if the variant allele frequency is <5% for SNVs and <15% for short insertions or deletions (indels), or if the variant has been identified as being out of the reportable range of the assay. Different approaches can be used in each study, and the Lab Team should discuss with the Study Coordinator how to set up review procedures in accordance with the study protocol.
Once the lab review is completed, the accept/reject status for all aMOIs for the patient is entered into OpenGeneMed and an email notification is sent to the treatment review team, indicating that the lab has approved the variant report and it is ready to be used to define the patient's treatment plan.
The Treatment Review Team members log into OpenGeneMed and look up the patient's aMOI report, the clinical data for treatment-specific ineligibilities and prior therapies. The rules governing genomic profiling, definitions of actionable mutations and treatment arms are all pre-defined in the study protocol. The rules also cover how treatments are selected in cases where multiple actionable variants occur.
After the mutation summary report has been completed, the Treatment Review Team selects the appropriate treatment and records the decision in OpenGeneMed, where the Clinic Team can read the information and deliver the selected treatment to the patient. During the trial, the clinic team will update the treatment report on the clinical information page to document the treatment assignment and the response data.
In the default configuration of OpenGeneMed, the Clinic Team is blinded to the sequencing assay report as sharing the sequencing results upfront would break the masking needed for randomized studies. This could endanger the validity of a randomized comparison, as patients might preferentially drop out or be taken off the control arm before evaluation of the primary endpoints of disease progression and tumor response. At disease progression, the sequencing results can be shared with the patient and the treating physician. OpenGeneMed is designed to manage both randomized and non-randomized studies and it does not implement any randomization assignment by default. Even in non-randomized studies, it may be important to prevent the Clinic Team to have direct access to the sequencing results before treatment. If this behavior does not align with the specific needs of a study, the visibility of the sequencing results can be easily changed by customizing OpenGeneMed source code (refer to the Technical User Manual for more details).
OpenGeneMed implements the delinking procedure that is essential to de-identify the collected information. In the NCI-MPACT trial, research-grade whole-exome sequencing is performed for all patients once they are off study. Because the whole-exome sequencing is not done in a CLIA lab, the sample identification must be delinked from the patient's clinical ID. We implemented the delinking process in OpenGeneMed following the same steps as in GeneMed, but this feature can be turned off for a simpler study that does not require de-identification.
The implemented delinking process takes three simple steps: a member of the clinic team initiates the delinking request through OpenGeneMed, the Clinic Team chief receives the notice from OpenGeneMed and issues approval after determining that the patient is ready to be delinked (i.e. all of the clinical information has been correctly added to the system); a second notice is sent to the Lab chief who will be the one to complete the delinking process. All research specimens in the lab need to be relabeled with the new ID (generated automatically by the system when the delinking request is issued) as the research lab should not keep any record that can be linked to the original patient ID.
Once the lab completes the delinking of the actual specimens, the lab chief logs back into OpenGeneMed to confirm the delinking. At that point, all records of the clinical ID will be automatically scrubbed from OpenGeneMed and replaced with the new ID in all database tables: at this point there will be no way of going back and connecting the delinked ID with the original patient ID. Delinking anonymizes the entry and allows follow-up studies with the specimens and data.
During the trial, the biostatisticians can log into OpenGeneMed to get the updated patient outcome data and sequencing data of all those patients who has been delinked because of disease progression or because they are off study. The biostatisticians can also access the system to view aggregate data of active patients to monitor accrual rate and make suggestions to the study coordinator if changes to the protocol or to the recruitment methods are needed.
The information is presented through dynamic pie charts, bar charts and table views that offer an interactive way of looking at the data. For more information about this feature, we refer to the "Usage examples" Section and Figure 7 .
Customizing study's specific information
As one of the first steps in using OpenGeneMed to handle a specific research study, the Study Coordinator should enter key information about the study in the system. In particular, the information that needs to be entered is divided into four groups:
1. Gene/Drugs: a table collecting information about the genes of interest in the study, their pathway, role and the drug that a mutation of this gene may be associated to.
Actionable Mutations: a table collecting information about
SNVs and insertion/deletion variants (indels) considered 'actionable' for the study. 3. Eligibility Questions: collection of yes/no questions assessing eligibility criteria for the study. 4. Actionable Rules: a collection of statements declaring which variants should be marked as 'actionable' for the specific study.
The identification of appropriate Actionable Rules, Gene/ Drugs and Actionable Mutations depends on the study in question, and it is part of the definition of the study protocol and the question of the study. The information usually comes from literature research about the biology of the disease of interest, pre-clinical studies and/or approved drugs. OpenGeneMed provides an easy-to-use interface to input this information in the system, but the origin of the data is the Study Coordinator's responsibility.
Actionable Rules, Gene/Drugs, Actionable Mutations and Eligibility questions should be properly completed at the beginning of the study, before any patient is recruited. However, it is possible that the information in these tables needs to be changed as the study progresses, to account for amendment of the study protocol, new information, etc. The impact of editing any entry in these tables is pervasive and it must be done with great care. OpenGeneMed keeps track of the last modification to the tables, comparing it with the time of any existing variant call report and patient information data. If, for example, a sample has been uploaded at time t1 and the actionable rules or gene/drugs table is changed at a later time t2, the validity of the variant calling may have been compromised (as the change may or may not affect what is determined to be an 'actionable mutation of interest'). OpenGeneMed will prompt the Lab Member reviewing the variant call that a mismatch may be possible and it is up to the Lab Team Chief to decide what action to take: either ignore the warning and proceed reviewing the current variant report, or rerun the variant call with the updated information. This decision has to be made after the Lab Team Chief contacts the Study Coordinator to understand the nature of the change. Note that any future upload of samples will automatically use the new updated information: the problem only arises for samples previously uploaded and reviewed with old information, but not re-reviewed with the newly updated information. A similar situation happens when eligibility questions are updated after a patient has been registered and his/her answers have already been recorded: OpenGeneMed will show the inconsistency to the Clinic Team member and his/her action to ignore the warning or to change the existing answer has to be decided in conjunction with the Study Coordinator who issued the changes.
Information for Actionable Rules, Gene/Drugs, Actionable Mutations and Eligibility questions can be easily added, deleted or edited by the Study Coordinator. Below we present some examples on how to customize Actionable Rules. For detailed instructions on how to customize the other tables, please refer to the technical documentation provided with the OpenGeneMed distribution.
In the initial setup of the study, only one custom actionable rule is listed. To add a new rule, the Study Coordinator should access the 'Add entry' tab under the 'Actionable Rules' task. The information entered for each rule is displayed in Figure 3 .
Rules can be simple and contain one single clause or can represent more complex logic.
All the clauses within a rule are combined with 'AND' logic. Exclusion rules are internally negated and listed as inclusion of their negated counterpart. The presence of multiple clauses on the same field may lead to incoherent definitions (i.e. conflicting clauses may lead to a definition of an empty set or redundant clauses may be present). OpenGeneMed implements some basic validation to alert the user for possibly incoherent rules. One example of this situation is shown in Figure 4 .
When the Study Coordinator clicks 'Submit', the validation is executed and a warning is displayed: the user must then decide whether to fix the error or to save the rule anyway.
The collection of all defined rules is combined with 'OR' logic, meaning that during the variant calling steps any variant meeting at least one of the different rules will be marked as actionable (aMOI ¼ 'yes'). This is the reason why any incoherent rule may be, per se, not that critical to the overall variant calling result. However, as those incoherencies may be the result of mistype or other human errors, OpenGeneMed marks them as possible issues.
Customizing the source code to adapt to different study designs A powerful feature of the OpenGeneMed system is that it is opensource and the modular design of the source code allows easy customization for different study designs. This requires coding experience, and in this section we outline just a few ideas on how OpenGeneMed is written using Perl (with DBIX and Mojolicious as the main libraries), and uses Javascript, CSS and D3 for the web interface. To customize the code, developers need to get familiar with these languages and libraries as well as MySQL (used for the back-end database management).
OpenGeneMed's different components need to be stored in specific locations of the file system. The technical documentation contains a list of the major directories with their relevant content and usage. Most of the user roles and tasks listed in the previous sections have a direct correspondent in a Perl object with a name that should clarify the connection. For example, the controller named Clinicteam.pm is a gateway file containing pointers to different tasks assigned to the Clinic Team. Each task is then coded into a separate file (Assignedt.pm is the controller that visualizes the assigned treatments, Eligibility.pm is the controller used to manage patients' eligibility answers, Patients.pm is the controller used to manage patients' clinical information, etc.).
Code customization can be classified into the following categories (ranked from the simplest to the most complex): An example for each customization is presented in the technical documentation of OpenGeneMed. Each of them requires a limited set of changes/additions, in files that are logically connected to the task undergoing modification (e.g. adding validation rules for the patient ID requires a small change in a validating subroutine of the Patient.pm module). The modular design and architecture of the project also facilitates addition of entirely new features and roles.
Usage examples
This section contains a few examples on how to use the default configuration of OpenGeneMed. More details for each role and each task are presented in the technical documentation distributed with the system. We present here some examples to give the reader a better understanding of how the system supports the everyday tasks of managing a research study.
In the basic initial setup, eight accounts are added for demo purposes.
Once a member of the Admin team logs into the system, the complete list of tabs and features of OpenGeneMed is displayed ( Figure 5 ). Note that each user/role has access only to specific parts of OpenGeneMed, but the Admin team can see all the different tabs belonging to all the other users. This is granted with the idea of administrators being able to quickly assess issues encountered by any user of the system. However, editing of samples' data, patient information and treatments should be done exclusively by authorized people.
Several tasks and roles have information displayed in tables. Across OpenGeneMed, tables have a consistent look and behavior. Editing and deleting entries is as easy as clicking the 'Edit' or 'Delete' button of the row that needs to be updated.
The table is sortable (by clicking the column headers) and filters can be activated just by typing the string that needs to be found in the proper search box. If the table is long, it will be automatically divided into pages that can be navigated using the page numbers in the lower right corner of the table (the number of visible rows can also be changed as needed). A 'Show/Hide columns' button on the top right corner of the tables allows to activate/deactivate the visibility of columns at any given moment.
Another example of how OpenGeneMed collects and displays relevant information is shown in Figure 6 . Figure 6 displays what a member of the Lab Team would see, after uploading a VCF file and after the OpenGeneMed annotates the file. Embedded hyperlinks for each variant enable direct link to online COSMIC databases, and manual review of variants. The shows the current variants found in samples uploaded in the system. The pie chart is dynamic and slices' visibility can be toggled on/off. (3) Dynamic bar chart with the same information and (4) a table containing the same information for ease of query (5) Additional information about selected variants can be retrieved by clicking the appropriate button, (6) As a final example of a unique feature of OpenGeneMed, we present how the system displays aggregate information about the variants of interest in the current study (Figure 7) . Information about patients' treatment assignments and variants not defined as actionable but interesting for further investigation are also displayed with similar dynamic charts. For more details about these, please refer to the technical documentation distributed with OpenGeneMed.
Conclusion and future work
Over the past decade, NGS has emerged as an essential tool for diagnosis and treatment selection for patients with cancer and other diseases. Developing drugs targeting specific genomic alterations in tumors is at the core of precision medicine approaches to cancer. Platforms that provide annotation capability as well as support in coordinating the management of a clinical study are essential for the success of these complex operations.
We developed OpenGeneMed: a customizable, open-source platform that streamlines clinical trial management and it can be used by clinicians, lab personnel, statisticians and other researchers as a communication hub. It automates the annotation of the genomic variants identified by sequencing, classifies the actionable mutations according to customizable rules and facilitates quality control by the molecular characterization lab in the review of variants.
Current and future development of OpenGeneMed is directed at including additional functionalities in its 'out-of-thebox' installation. Changes include uploading VCF files having different formats and adding functional annotation information with tools like SIFT [21] , an algorithm that performs functional predictions for known polymorphisms as well as de novo somatic mutations detected by the assay.
Key Points
• OpenGeneMed is an informatics system designed to support clinical trials involving genomic-driven treatment selection.
• OpenGeneMed streamlines clinical trial management and it can be used by clinicians, lab personnel, statisticians and other researchers as a communication hub.
• OpenGeneMed is distributed as a stand-alone virtual machine, ready for deployment. Its modular code allows customization of existing features and addition of modules to address the specific needs of different clinical trials and research teams.
• OpenGeneMed translates and presents the mutation findings from sequencing results into a concise and easy-to-read actionable report for the treatment review team.
• OpenGeneMed annotates the sequencing data and matches the detected mutations to pre-identified genomic changes marking them as 'actionable mutations of interest'.
